|Bid||1.4300 x 800|
|Ask||1.6500 x 800|
|Day's Range||1.3700 - 1.4900|
|52 Week Range||1.3600 - 8.0800|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 03, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Subscribe to Yahoo Finance Plus to view Fair Value for LCILearn more
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 second quarter on Thursday, February 3, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that they have completed the safety review of the Investigational New Drug (IND) application for biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC), and concluded that the company may proceed with the proposed clinical investigation. The company said it anticipates the pivotal clin